Current Perspectives on the Use of Anti-VEGF Drugs as Adjuvant Therapy in Glaucoma

The approval of one of the first anti-vascular endothelial growth factor (VEGF) agents for the treatment of neovascular age-related macular degeneration one decade ago marked the beginning of a new era in the management of several sight-threatening retinal diseases. Since then, emerging evidence has...

Descripción completa

Detalles Bibliográficos
Autores principales: Andrés-Guerrero, Vanessa, Perucho-González, Lucía, García-Feijoo, Julián, Morales-Fernández, Laura, Saenz-Francés, Federico, Herrero-Vanrell, Rocío, Júlvez, Luis Pablo, Llorens, Vicente Polo, Martínez-de-la-Casa, José María, Konstas, Anastasios-Georgios P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331081/
https://www.ncbi.nlm.nih.gov/pubmed/28000166
http://dx.doi.org/10.1007/s12325-016-0461-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5331081/
https://www.ncbi.nlm.nih.gov/pubmed/28000166
http://dx.doi.org/10.1007/s12325-016-0461-z

Ejemplares similares